Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Acq. announced
Vistagen Therapeutics, Inc. (VTGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2020 8-K Quarterly results
08/14/2020 8-K Quarterly results
04/03/2020 8-K Investor presentation
Docs: "VistaGen Therapeutics, Inc. Corporate Presentation, dated April 2020"
12/27/2019 8-K Quarterly results
05/02/2019 8-K Investor presentation
Docs: "PRESENTATION",
"VistaGen Reports Top Line Results from NIMH’s Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression SOUTH SAN FRANCISCO, Calif., May 2, 2019 - VistaGen Therapeutics , a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system diseases and disorders with high unmet need, today announced top line results from an exploratory Phase 2 clinical study of AV-101 as a monotherapy in patients with treatment-resistant depression . In the 19-patient study sponsored and conducted by the U.S National Institute of Mental Health , AV-101 did not demonstrate significant separation from placebo on the primary outcome measure, the change from baseline in the Hamilton Depression Rating Scale total..."
03/14/2019 8-K Investor presentation
Docs: "Corporate Presentation",
"VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101 SOUTH SAN FRANCISCO, Calif., March 13, 2019 - VistaGen Therapeutics , a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system diseases and disorders with high unmet need, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 15/812,599 related to certain methods of production for AV-101, VistaGen's oral NMDA receptor glycine site antagonist in Phase 2 development for major depressive disorder . The patent, once issued, will expand upon the related claims obtained in U.S. Patent No. 9,834,801 granted to VistaGen by the USPTO in December 2..."
01/11/2019 8-K Investor presentation
Docs: "Corporate Presentation, dated January 2019"
09/18/2018 8-K Investor presentation
Docs: "Corporate Presentation, dated September 2018"
01/08/2018 8-K Investor presentation
Docs: "VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder South San Francisco, CA – VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AV-101 for development as a potential adjunctive treatment for Major Depressive Disorder . The FDA’s Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as MDD. “Fast Track Designation is another important regulatory milestone for our AV-101 program for MDD, providing us the opportuni...",
"Corporate Presentation, dated January 2018"
06/16/2015 8-K Investor presentation
Docs: "Investor Presentation of VistaGen Therapeutics, Inc"
03/16/2015 8-K Investor presentation
Docs: "Investor Presentation of VistaGen Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy